Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TVEC-325: Imlygic in Unresected Melanoma
NCT02366195Phase 2Completed
- Sponsor
- Amgen
- Start
- Apr 2015
- Primary completion
- Jun 2017
- Modality
- Oncolytic Viruses
- Countries
- 13
01
Overview
Phase 2, open-label, single-arm trial of talimogene laherparepvec in melanoma, sponsored by Amgen. Primary endpoint: Odds Ratio of Baseline Intratumoral CD8+ Cell Density and Objective Response Rate up to 116 weeks. Started Apr 2015; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02366195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02366195.